Aug. 14 at 1:02 PM
$NEO Wall Street analysts have collectively raised earnings per share estimates by 1.4% over the past 30 days—a bullish sign suggesting improving sentiment.
Technicals turned bullish yesterday. NeoGenomics holds a strong Zacks buy rating, placing it in the top 20% of all stocks in terms of recent earnings estimate trends and surprise potential.
In Q1 2025, revenue rose 8% year-over-year to
$168M, and adjusted EBITDA soared 102% to
$7M—marking consecutive positive quarters. Meanwhile, net losses narrowed and cash reserves remain strong at
$358M.
Based on discounted cash flow, the stock trades at only 10% of its estimated
$75.44 fair value—a striking 90% undervaluation.
The Pathline acquisition adds
$12–14M in annual revenue with synergies into high-margin testing.
NeoGenomics shows multiple bullish indicators, both technical and fundamentalp
